Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)

Ultimovacs ASA announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in NSCLC.